A new trial to find a treatment for Type 1 diabetes has started at Guy’s Hospital in London.
The phase one clinical trial is for a new immunotherapy treatment, called MultiPepT1De, which will target the autoimmune attack that leads to the development of the condition.
The new therapy will use peptides - fragments of proteins - in an effort to stop this process by ‘switching off’ the specific autoimmune attack, and hopefully preventing further destruction of the pancreatic cells.
Anna Morris, interim Director of Research at Diabetes UK, said: “The MultiPepT1De trial is a significant first step towards the development of a therapy which could slow or stop the progression of Type 1 diabetes. While this is at an early stage, we’re very much looking forward to seeing the results of this groundbreaking trial. Research in this area has the potential to transform the lives of people living with Type 1 diabetes.”
MultiPepT1De will be trialled on 24 people with Type 1 diabetes by autumn 2016, and is designed to benefit a higher proportion of those with the condition than its predecessor trial.